Northern, WI  1/8/2013 (BasicsMedia) – taking a look at the morning movers we find the Perion Network Ltd. (PERI) hitting a few high notes up some 20% on a volume so far around 1.7 million. Today Perion Network Ltd. announced their revenue estimates for 2012 and its guidance for 2013. Taking a look at the Revenues in the fourth quarter of 2012 Perion said they expect to reach a record $21 million which is more than double the fourth quarter of 2011. Accordingly this will bring their total non-GAAP revenues for 2012 to $61 million, which is an increase of 64%, from $37 million in 2011.

Some of the announced highlights include revenue which  is expected to exceed $110 million, representing overall growth of 80%+ year over year. The company’s EBITDA is expected to be at least $26 million, representing an EBITDA margin of 24%. Their Non-GAAP Net Income is expected to be at least $20 million, representing an 18% net profit margin and their Non-GAAP EPS is expected to be at least $1.61, based on an average of 12.4 million shares outstanding

Mr. Josef Mandelbaum, Perion’s CEO commented saying, “We are very excited about 2013 and expect it to be a breakout year in terms of growth both in top and bottom line results. Our improving financial results are a result of our strong organic growth coupled with our acquisition strategy and a diversified product portfolio with multiple revenue streams”.

Another leading gainer out of the gate this morning is Cell Therapeutics Inc. (CTIC). Cell is up 18% this morning while trading over 13 million shares so far, their daily average is right around 1.6 million. Cell Therapeutics is a company that engages in the development, acquisition, and commercialization of drugs for the treatment of cancer. Pixuvri is one of the drugs the company is developing. Pixuvri is a novel anthracycline derivative for the treatment of hematologic malignancies and solid tumors. The Cell Therapeutics has also teamed up with Chroma Therapeutics, Ltd. which is developing Tosedostat, an oral aminopeptidase inhibitor. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.

Seems like a lot of study results are coming in during the first part of this year.  Star Scientific, Inc. (STSI) has joined the crowded room announcing the preliminary results of their Anatabloc Supplementation Autoimmune Prevention Human Thyroid Study which  analyzes the impact of anatabine dietary supplementation on thyroid health. The company’s per share price is up some 7% in early morning trading. This is a three-month, five-visit, double-blind, placebo-controlled study of the impact of anatabine dietary supplementation in humans with autoimmune disease of the thyroid.  The study was conducted at nine sites and builds upon previous epidemiological and animal experimental studies.  Initial results for all study subjects suggest that dietary supplementation with anatabine ameliorates the immune system’s targeting of the thyroid gland in autoimmune thyroiditis.

Disclaimer:  We have no position in any stock mentioned here.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.